10-12 September 2018 //  Lancaster Royal Hotel, London


Aniz Girach

Dr Aniz Girach

Chief Medical Officer, NightstaRx

Aniz Girach, qualified as an Ophthalmologist (specialty in Retina), and worked in Cambridge (UK).

After having spent 11 years in academia, he joined the pharmaceutical industry with Eli Lilly, focusing on retinal diseases. He has in total 20 years industry experience in roles with Merck (as their Global Head of Ophthalmology) and Alcon, where he was Vice President of Clinical Development, and ThromboGenics, where he was the Global Head of Ophthalmology/Chief Medical Officer overseeing the development and approval of Ocriplasmin (Jetrea)—a first in class biologic therapy for retinal disease. In addition to an Honorary Professorship at Wills Eye Hospital, Philadelphia, USA, he is currently the Chief Medical Officer at NightstaRx, overseeing the development of gene therapies for inherited retinal diseases.

He is a member of 3 Scientific Advisory Boards for international ophthalmic organizations currently, and reviewer for 5 peer-reviewed journals, including Eye and IOVS. He has edited 4 books and published over 60 abstracts/manuscripts in peer-reviewed journals in Ophthalmology, with numerous invited lectures at national/international ophthalmology meetings.

His special interests are Medical Retina, Vitreomacular Interface Abnormalities and Gene Therapy.

2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad